Trial · NCT03753919
Adverse events552
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 552
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Fatigue | General disorders | COHORT 1: Durvalumab + Tremelimumab | 16 | 37 | 16 |
| other | Fatigue | General disorders | COHORT 1: Durvalumab Monotherapy | 0 | 26 | 0 |
| other | Fatigue | General disorders | COHORT 2: Durvalumab + Tremelimumab | 10 | 30 | 10 |
| other | Fatigue | General disorders | COHORT 2: Durvalumab Monotherapy | 0 | 25 | 0 |
| other | Fatigue | General disorders | COHORT 3: Durvalumab + Tremelimumab | 7 | 12 | 7 |
| other | Fatigue | General disorders | COHORT 3: Durvalumab Monotherapy | 0 | 10 | 0 |
| other | Pruritus | Skin and subcutaneous tissue disorders | COHORT 1: Durvalumab + Tremelimumab | 10 | 37 | 10 |
| other | Pruritus | Skin and subcutaneous tissue disorders | COHORT 1: Durvalumab Monotherapy | 0 | 26 | 0 |
| other | Pruritus | Skin and subcutaneous tissue disorders | COHORT 2: Durvalumab + Tremelimumab | 14 | 30 | 14 |
| other | Pruritus | Skin and subcutaneous tissue disorders | COHORT 2: Durvalumab Monotherapy | 0 | 25 | 0 |
| other | Pruritus | Skin and subcutaneous tissue disorders | COHORT 3: Durvalumab + Tremelimumab | 3 | 12 | 3 |
| other | Pruritus | Skin and subcutaneous tissue disorders | COHORT 3: Durvalumab Monotherapy | 0 | 10 | 0 |
| other | Diarrhea | Gastrointestinal disorders | COHORT 1: Durvalumab + Tremelimumab | 9 | 37 | 9 |
| other | Diarrhea | Gastrointestinal disorders | COHORT 1: Durvalumab Monotherapy | 0 | 26 | 0 |
| other | Diarrhea | Gastrointestinal disorders | COHORT 2: Durvalumab + Tremelimumab | 14 | 30 | 14 |
| other | Diarrhea | Gastrointestinal disorders | COHORT 2: Durvalumab Monotherapy | 0 | 25 | 0 |
| other | Diarrhea | Gastrointestinal disorders | COHORT 3: Durvalumab + Tremelimumab | 2 | 12 | 2 |
| other | Diarrhea | Gastrointestinal disorders | COHORT 3: Durvalumab Monotherapy | 0 | 10 | 0 |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | COHORT 1: Durvalumab + Tremelimumab | 10 | 37 | 10 |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | COHORT 1: Durvalumab Monotherapy | 0 | 26 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03753919/events